Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ruboxistaurin

Home DrugsRuboxistaurin

Investigational

Small Molecule

Ruboxistaurin

Unknown Manufacturer

Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.

Technical identifiers

Chemical Formula: C₂₈H₂₈N₄O₃
CAS Number: 169939-94-0
UNII ID: 721809WQCP

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS
EP 4525862 A4Applicant: DERMBIONT INCPriority: 2022
EP
US
WO
6 publications
POLYMORPHS OF N-DESMETHYL RUBOXISTAURIN AND SALTS THEREOF
EP 4698538 A1Applicant: 4M THERAPEUTICS INCPriority: 2023
EP
US
WO
3 publications
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
US 9265764 B2Applicant: HAGGARTY STEPHEN JPriority: 2010
US
2 publications
Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
US 9562015 B2Applicant: UNIV COLORADO REGENTSPriority: 2012
US
2 publications
Methods For Diagnosing And Treating Diabetic Microvascular Complications
US 2008096923 A1Applicant: GIRACH ANIZPriority: 2005
US
Combination Therapy for Vascular Complications Associated with Hyperglycemia
US 2007281988 A1Applicant: CAMERON NORMAN EPriority: 2005
US
Combination Methods for Preserving Visual Acuity
US 2008234351 A1Applicant: SHEETZ MATTHEW JOHNPriority: 2006
US
Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
US 2008312241 A1Applicant: GILEAD SCIENCES INCPriority: 2008
US
DEUTERIUM-ENRICHED RUBOXISTAURIN
US 2012136037 A1Applicant: CZARNIK ANTHONY WPriority: 2008
US
Method of manufacturing ruboxistarin
EP 2181999 A1Applicant: ZENTIVA KSPriority: 2008
EP

Page 1 of 2